Equities

Nektar Therapeutics

Nektar Therapeutics

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.30
  • Today's Change0.03 / 2.36%
  • Shares traded2.40m
  • 1 Year change+83.10%
  • Beta0.5996
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments304505734
Total Receivables, Net1.215.9822
Total Inventory161916
Prepaid expenses------
Other current assets, total9.781623
Total current assets331546796
Property, plant & equipment, net3786178
Goodwill, net07777
Intangibles, net------
Long term investments26065
Note receivable - long term------
Other long term assets4.642.252.74
Total assets3987111,117
LIABILITIES
Accounts payable9.85139.75
Accrued expenses415575
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities516885
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total216276352
Total liabilities267344438
SHAREHOLDERS EQUITY
Common stock0.020.020.02
Additional paid-in capital3,6083,5753,517
Retained earnings (accumulated deficit)(3477)(3201)(2833)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.08(6.91)(4.16)
Total equity131367680
Total liabilities & shareholders' equity3987111,117
Total common shares outstanding191189185
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.